Neuren Pharmaceuticals (NEU) investor relations material

Executive summary

• Achieved profit after tax of $30.4 million for 2025, down from $142.0 million in 2024, reflecting lower milestone and voucher revenues year-over-year.

• Revenue from contracts with customers was $64.6 million, compared to $213.2 million in 2024, as prior year included significant milestone and voucher payments.

• Maintained strong liquidity with $4.2 million in cash and $291.9 million in short-term investments at year-end.

• Initiated and completed a share buy-back program, repurchasing 3.27 million shares for $50 million.

Financial highlights

• Revenue from contracts with customers: $64.6 million (2025) vs $213.2 million (2024).

• Net profit after tax: $30.4 million (2025) vs $142.0 million (2024).

• Basic EPS: 23.73 cents (2025) vs 111.17 cents (2024).

• Operating cash flow: $125.4 million (2025) vs $(11.3) million (2024).

• Total assets: $342.9 million (2025) vs $409.7 million (2024).

Outlook and guidance

• Directors confirm the group has adequate resources to meet obligations for at least 12 months from signing.

• Eligible for future milestone payments up to US$300 million and ongoing royalties from Acadia partnership.

• Announced intention to commence a new on-market share buy-back program post year-end.